Abstract: Provided is a highly reliable technique for the evaluation of ischemic conditions. A preferred embodiment is a nuclear medicine measurement protocol in which the administration of a radiopharmaceutical agent and radiation measurement are performed twice at rest and under stress. In the nuclear medicine measurement protocol, radiation collection is performed without radiopharmaceutical agent administration before the second radiopharmaceutical agent administration, and the result is used to correct the nuclear medicine measurement result after the second radiopharmaceutical agent administration.

Abstract: Provided is a method for producing flutemetamol including the steps of: reacting a precursor compound represented by a predetermined general formula with a radioactive fluoride to obtain a 18F labeling compound represented by a predetermined general formula; allowing a strong base to act on the reaction mixture of the above step containing the precursor compound and the 18F labeling compound; after the above step, purifying the 18F labeling compound using a reverse phase solid phase extraction cartridge; and removing a protective group to obtain [18F]flutemetamol.

Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.

Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: There is provided a labeling precursor compound represented by the following general formula (2): wherein R1 represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R2 and R3 each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R6 represents an alkyl group or —CONR11R12 wherein R11 and R12 each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R4, R5, R7 and R8 each independently represent a hydrogen atom, an alkyl group or an alkoxy group.

Abstract: The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: In imaging analysis of a living body, a Region Of Interest (ROI) is set on the basis of the state of radiopharmaceutical accumulation. An example for setting an ROI includes: performing first transformation for anatomically standardizing, with the use of a positive template, a nuclear medicine image acquired by applying a radiopharmaceutical to a subject; performing second transformation for anatomically standardizing, with the use of a negative template, the nuclear medicine image; calculating a degree of similarity between a first anatomical standardization image acquired by the first transformation and the positive template; calculating a degree of similarity between a second anatomical standardization image acquired by the second transformation and the negative template; and applying, to an ROI template, inverse transformation of the first transformation or the second transformation, whichever has the higher of the calculated degrees of similarity, in order to set the ROI.

Abstract: Provided is a method for imaging a renal lesion comprising the steps of administrating a nitroimidazole-based compound to a living body and obtaining an image of the renal lesion by detecting radiation non-invasively from the outside of the living body wherein the renal imaging agent comprises a defined nitroimidazole-based compound or a salt thereof. The step of obtaining the image of the renal lesion can include using positron emission tomography.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: An apparatus for producing a radiolabeled compound is a production apparatus which produces a radiolabeled compound by introducing a radioisotope into a non-radioactive labeling precursor compound. The production apparatus includes a solid phase extraction unit in which a specific process which is a reaction of an intermediate compound, a purification of the intermediate compound, or a purification of the radiolabeled compound is carried out; and a cooling unit that cools the solid phase extraction unit, when the specific process is carried out.

Abstract: There is provided a diagnostic imaging agent for early bone metastasis from cancer, containing trans-1-amino-[18F]fluorocyclobutanecarboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Abstract: The present invention provides a renal imaging agent comprising a nitroimidazole-type compound or a salt thereof. The renal imaging agent according to the present invention can be used in positron emission tomography.

Abstract: Provided is a method for producing an animal model of osteoblastic bone metastasis. A non-human animal in which an osteoblastic lesion is formed in a wide range has been successfully produced with a probability of 100% by: administering a calcineurin inhibitor to a non-human animal; and injecting a tumor cell into an artery or a vein of the non-human animal, wherein the non-human animal and the tumor cell are in an allogeneic or xenogeneic relation.

Abstract: Disclosed is a target device (10) having a plurality of target material plates (20a, 20b) for producing a radionuclide, lined up in an overlapped manner, configured to produce the radionuclide when a particle beam is irradiated on the target material plates (20a, 20b), the target device (10) having a front plate group (GRF) composed of target material plates (20a) positioned to the front side the particle beam comes in, and a rear plate group (GRR) composed of the target material plates (20b) positioned to the rear side, and the average thickness of the target material plates (20a) composing the front plate group (GRF) being smaller than the average thickness of the target material plates (20b) composing the rear plate group (GRR).

Abstract: To provide a technique for evaluating a nuclear medicine brain image, the technique being hardly affected by the difference in the setting of reference regions. An embodiment of the present invention generally includes: setting a reference region on a region corresponding to the scalp in the nuclear medicine brain image; calculating information on a pixel value in the set reference region; and normalizing, using the information, a pixel value of each pixel included in the nuclear medicine brain image or a value obtained from the pixel value, and outputting the normalized value.

Abstract: Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R1, R2, R3, R4, R5, X1, X2, and X3 are defined.

Abstract: There is provided a labeling precursor compound represented by the following general formula (2): wherein R1 represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R2 and R3 each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R6 represents an alkyl group or —CONR11R12 wherein R11 and R12 each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R4, R5, R7 and R8 each independently represent a hydrogen atom, an alkyl group or an alkoxy group.

Abstract: One of the preferred embodiments includes: (a) creating a summed 3D nuclear medicine imaging data by summing a plurality of 3D nuclear medicine imaging data pixel by pixel; (b) determining pixels corresponding to myocardial regions in the summed 3D nuclear medicine imaging data; (c) defining a plurality of tracing directions based on the summed 3D nuclear medicine imaging data, and determining a reference myocardial center base point, a reference inner myocardial wall base point and a reference outer myocardial wall base point for each of the tracing directions; (d) determining a phase-specific myocardial center base point for each of the tracing directions for each of the phases; and (e) seeking a difference between the reference myocardial center base point and the phase-specific myocardial center base point, and determining a phase-specific inner myocardial wall base point and a phase-specific outer myocardial wall base point.